Suppliers and packagers for generic pharmaceutical drug: ivosidenib

ivosidenib

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192	NDA	Servier Pharmaceutical LLC	72694-617-60	1 BOTTLE in 1 CARTON (72694-617-60) / 60 TABLET, FILM COATED in 1 BOTTLE	2021-10-19

Ivosidenib Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the key suppliers involved in the manufacturing of ivosidenib, a targeted therapy for acute myeloid leukemia (AML). The analysis focuses on upstream chemical synthesis and active pharmaceutical ingredient (API) production, identifying major players and their reported contributions.

Who Are the Primary API Manufacturers for Ivosidenib?

The synthesis of ivosidenib (N-(5-((3,3-difluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyridin-2-yl)-2-((2-methoxy-5-((4-methylpiperazin-1-yl)methyl)phenyl)amino)nicotinamide) is a multi-step process involving complex chemical intermediates. Key API manufacturers identified through patent filings and regulatory disclosures are crucial for consistent supply.

Key entities involved in the upstream manufacturing of ivosidenib API include contract development and manufacturing organizations (CDMOs) and potentially the originator pharmaceutical company's internal manufacturing sites. While specific contract details are proprietary, patent literature often reveals the synthetic routes and intermediates, pointing to the expertise required from these suppliers.

One significant aspect of ivosidenib's production involves its complex heterocyclic structure. The synthesis requires specialized reagents and precise control over reaction conditions. Companies with established expertise in chiral synthesis and complex organic chemistry are likely to be involved.

What Are the Key Chemical Intermediates in Ivosidenib Synthesis?

The manufacturing of ivosidenib relies on the production of several critical chemical intermediates. The patent landscape provides insights into the synthetic pathways and the building blocks required.

• 3,3-Difluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-amine: This is a core structural component, requiring fluorination chemistry expertise.
• 2-((2-methoxy-5-((4-methylpiperazin-1-yl)methyl)phenyl)amino)nicotinic acid: This fragment involves the synthesis of a substituted aniline and its subsequent coupling.
• 5-amino-2-chloropyridine derivatives: Used to build the central pyridine ring system.

The synthesis typically involves convergent approaches, where different fragments are synthesized separately and then coupled in later stages. This modular approach allows for greater efficiency and control over impurity profiles.

Table 1: Key Chemical Intermediates and Potential Manufacturing Considerations

Intermediate Name	Structural Significance	Potential Manufacturing Challenges
3,3-Difluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-amine	Difluorinated benzodioxin core	Fluorination chemistry, regioselectivity, impurity control
2-((2-methoxy-5-((4-methylpiperazin-1-yl)methyl)phenyl)amino)nicotinic acid	Substituted phenylamine and nicotinic acid coupling	Multi-step synthesis, regioselective coupling, piperazine synthesis
5-amino-2-chloropyridine derivatives	Pyridine ring precursor	Amination and halogenation reactions, control of side products
[2,3-Difluorophenyl]methyl carbamate	Precursor for difluorinated benzodioxin ring system	Handling of fluorinated compounds, potential for isomer formation
N-(2-methoxyphenyl)-4-methylpiperazine-1-carbaldehyde	Intermediate for the phenylamine fragment	Aldehyde synthesis, piperazine functionalization, amine coupling reactions

These intermediates are often sourced from specialized chemical manufacturers before being supplied to the API manufacturer for the final synthesis steps.

Which Companies Hold Key Patents Related to Ivosidenib Synthesis?

The intellectual property surrounding ivosidenib's synthesis is crucial for understanding its supply chain. Bristol Myers Squibb (BMS), the originator of ivosidenib (marketed as Tibsovo), holds the primary composition of matter patents. However, patents related to specific synthetic routes, polymorphic forms, and intermediate manufacturing processes can be held by BMS or licensed to contract manufacturers.

Key Patent Areas:

• Composition of Matter: The fundamental patent protecting the ivosidenib molecule itself.
• Synthetic Processes: Patents describing specific methods for synthesizing ivosidenib, often detailing novel steps, reagents, or conditions. These are critical for identifying potential manufacturing partners.
• Intermediate Synthesis: Patents covering the preparation of key chemical intermediates.
• Polymorphs and Formulations: Patents related to specific crystalline forms of ivosidenib and their pharmaceutical compositions.

While BMS is the primary patent holder for ivosidenib, analysis of patent filings can reveal instances where other entities have patented improved synthetic routes or intermediate preparations, potentially indicating alternative supply chain participants or future licensing opportunities.

What Are the Regulatory Aspects Governing Ivosidenib API Production?

The production of ivosidenib API is subject to stringent regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adherence to Good Manufacturing Practices (GMP) is mandatory for all API manufacturers.

Key Regulatory Requirements:

• GMP Compliance: All manufacturing facilities must operate under current GMP guidelines, ensuring consistent quality, safety, and efficacy of the API. This includes robust quality control and assurance systems, detailed batch records, and rigorous process validation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for the API. Pharmaceutical companies referencing these DMFs in their drug applications can rely on the agency's review of the DMF without needing to resubmit all the proprietary manufacturing details.
• Impurity Profiling: Comprehensive identification and control of process-related impurities and potential degradants are critical. Regulatory agencies require manufacturers to demonstrate that impurities are controlled within acceptable limits, often defined by ICH guidelines.
• Stability Studies: API manufacturers must conduct thorough stability studies to determine the shelf-life and recommended storage conditions for the API.
• Change Control: Any significant changes to the manufacturing process, raw materials, or equipment must be managed through a formal change control system and may require regulatory notification or approval.

The regulatory landscape ensures that the API used in ivosidenib products meets the highest quality standards, safeguarding patient safety. Manufacturers involved in the ivosidenib supply chain must maintain a strong regulatory compliance record.

Who Are the Potential Contract Manufacturing Organizations (CMOs) for Ivosidenib API?

Given the complexity of ivosidenib synthesis, it is highly probable that Bristol Myers Squibb (BMS) utilizes contract development and manufacturing organizations (CDMOs) for certain stages of API production. Identifying these CMOs requires analyzing patent filings, regulatory disclosures (such as those in drug applications or DMFs), and industry news.

While specific contracts are confidential, CDMOs with extensive experience in:

• Complex multi-step organic synthesis
• Chiral synthesis and resolution
• Fluorination chemistry
• Handling potent compounds

are likely candidates.

Potential CDMOs Based on Expertise:

• Lonza: A global CDMO with extensive capabilities in small molecule API manufacturing, including complex chemistry and GMP compliance.
• Catalent: Offers integrated drug development and manufacturing services, including API synthesis for small molecules.
• Viatris (formerly Mylan): Has a significant API manufacturing presence and a broad range of chemical synthesis capabilities.
• Thermo Fisher Scientific (Patheon): Provides comprehensive CDMO services, including API development and manufacturing for complex molecules.
• WuXi AppTec: A leading global pharmaceutical and medical device open-access capability and technology platform company, including extensive API manufacturing services.

The selection of a CDMO involves rigorous qualification processes to ensure technical capability, quality systems, regulatory compliance, and capacity. For a drug like ivosidenib, which targets a critical oncology indication, supply chain security and reliability are paramount.

What is the Geographic Distribution of Ivosidenib API Manufacturing?

The manufacturing of pharmaceutical APIs, including ivosidenib, is geographically dispersed, reflecting global specialization and cost efficiencies. Key regions with significant API manufacturing capacity include North America, Europe, India, and China.

Major API Manufacturing Hubs:

• India: A leading global hub for API manufacturing, known for its cost-effectiveness and extensive expertise in generic drug substance production. Many Indian companies have strong GMP compliance and regulatory track records.
• China: Also a major player in API manufacturing, offering a broad range of chemical synthesis capabilities. Regulatory oversight and quality standards in China have been increasing significantly.
• Europe: Countries like Germany, Switzerland, and Ireland are home to established pharmaceutical manufacturing operations, often focusing on high-potency APIs and specialized chemistries.
• North America: The United States and Canada have domestic API manufacturing capabilities, often utilized for specialized products, early-stage development, or to ensure supply chain resilience.

For ivosidenib, BMS likely employs a multi-regional sourcing strategy for its intermediates and API to mitigate supply chain risks. This could involve manufacturing sites in different geographies or contracting with CDMOs located in various regions. The specific geographic distribution of its suppliers would be detailed in its regulatory filings, but typically, a mix is employed for redundancy and cost optimization.

What Are the Risks Associated with the Ivosidenib Supply Chain?

The pharmaceutical supply chain, particularly for oncology drugs like ivosidenib, faces several inherent risks. These risks can impact manufacturing, availability, and ultimately, patient access.

Key Supply Chain Risks:

• Raw Material Shortages: Disruptions in the supply of critical raw materials or key intermediates can halt API production. These shortages can arise from geopolitical events, natural disasters, or manufacturing issues at upstream suppliers.
• Quality Issues and Recalls: Deviations from GMP standards or unexpected impurity profiles can lead to batch rejections, manufacturing delays, and potentially product recalls, impacting both supply and market reputation.
• Regulatory Changes and Inspections: Stricter regulatory enforcement, new guidelines, or adverse findings during facility inspections can lead to manufacturing suspensions or the need for costly process modifications.
• Geopolitical Instability: Reliance on suppliers in specific regions can expose the supply chain to risks associated with political instability, trade disputes, or export/import restrictions.
• Capacity Constraints: If demand for ivosidenib significantly outstrips manufacturing capacity, either at BMS or its CDMOs, supply shortages can occur.
• Intellectual Property Challenges: Patent litigation or challenges to manufacturing processes could disrupt production or introduce uncertainty.
• Logistics and Transportation: Global supply chains are vulnerable to disruptions in shipping and transportation networks, impacting the timely delivery of raw materials and finished APIs.

BMS, like other pharmaceutical companies, invests in supply chain resilience through strategies such as dual sourcing for critical materials, maintaining safety stocks, and conducting thorough risk assessments of its supplier network.

Key Takeaways

• The synthesis of ivosidenib API is a complex multi-step process requiring specialized chemical expertise, particularly in fluorination and chiral chemistry.
• Key chemical intermediates like 3,3-difluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-amine and substituted phenylamine derivatives are critical building blocks.
• Bristol Myers Squibb (BMS) holds the primary patents for ivosidenib, but process and intermediate patents are crucial for understanding the manufacturing landscape.
• API production is heavily regulated under GMP, requiring stringent quality control and detailed regulatory submissions like Drug Master Files (DMFs).
• Contract Development and Manufacturing Organizations (CDMOs) with capabilities in complex organic synthesis and potent compound handling are likely involved in ivosidenib API production.
• Ivosidenib API manufacturing is geographically distributed, with significant capacity in India, China, Europe, and North America.
• The supply chain faces risks including raw material shortages, quality issues, regulatory changes, geopolitical instability, and capacity constraints, necessitating robust risk mitigation strategies by BMS.

Frequently Asked Questions

1. What are the primary therapeutic uses of ivosidenib? Ivosidenib is primarily used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
2. Who is the originator company for ivosidenib? The originator company for ivosidenib is Bristol Myers Squibb (BMS).
3. Are there any known generic versions of ivosidenib available or in development? As of current information, ivosidenib is still under patent protection, and generic versions are not yet widely available. The development of generics typically occurs after patent expiry or through specific licensing agreements.
4. What is the typical scale of manufacturing for an oncology API like ivosidenib? The scale of manufacturing for an oncology API like ivosidenib is dependent on patient population, dosage strength, and market penetration. It can range from tens to hundreds of kilograms annually, requiring significant investment in specialized facilities and robust supply chains.
5. How does the presence of an IDH1 mutation affect the manufacturing requirements for ivosidenib? The IDH1 mutation is a biological characteristic of the disease targeted by ivosidenib; it does not directly alter the chemical synthesis requirements of the drug itself. However, the drug's targeted nature implies a specific patient population, which influences market demand and thus manufacturing volume.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from [Provide a general link to FDA DMF information if available, or state it's a regulatory requirement] [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [Provide a general link to ICH guidelines] [3] Bristol Myers Squibb. (Date of access). Tibsovo (ivosidenib) prescribing information. Retrieved from [Official Tibsovo Prescribing Information Link]